MENU
YMAB
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Y-mAbs Therapeutics (YMAB) Ownership - Who owns Y-mAbs Therapeutics?
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company... Show more
Industry: #Pharmaceuticals Major
Profile
Industry
Pharmaceuticals Major
Address
230 Park Avenue
Phone
+1 646 885-8505
Employees
100
Web
https://www.ymabs.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
213.34M
P/E Ratio
N/A
Total Cash
60.31M
Projected Growth
N/A
Total Debt
603K
Revenue
88.66M
Risk (Beta)
-0.15
Dividend Yield
N/A
Total Cash/Share
1.33
Total Debt/Equity
N/A
Revenue/Share
1.99 USD as % of share price
Fundamentals
YMAB
Capitalization
213M
P/E Ratio
N/A
Risk (Beta)
-0.15
Dividend Yield
N/A
Total Cash
60.3M
Total Cash/Share
1.33
Total Debt
603K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
1.99%
Revenue
88.7M
ROE
N/A
Book Value
89.5M
P/B Ratio
2.38
Cash Flow
N/A
Earnings
-0.64
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
5K
Current Ratio
4.77
Current Revenue Per Employee
195364.48
Dividends Per Share - Security
N/A
EBITDA
-30.39M
Float
N/A
Float - Current
N/A
Gross Income Margin
85.64
Revenue To Assets
-23.93
Shares Held By Institutions
183M
Shares Outstanding - Current
45.3M
Total Liabilities
23.2M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-39.847
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a developer of novel antibody therapeutics for oncology targets
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
230 Park Avenue
Phone
+1 646 885-8505
Employees
100
Web
https://www.ymabs.com